Amarantus Bioscience Holdings Inc (AMBS)

[JPetroInc]

Risk, the entire point of the filing being in question opens the door to potential scrutiny by our current Pipe financiers and potential for adverse reactions from them. This is not a wish list. This is not lets make it up as we go along. This is a publicly traded company which must comply with mandatory SEC rules and reg's., or suffer the consequences from them.

Its understood, AMBS is an OTCBB bio-tech start-up. It also has the attention of some of the biggest Pharma names in the industry. Most recently, we garnered a $20-Mil. financial endorsement and shareholder friendly SEDA from one of the most respected financiers in the bio-finance arena. You can't get any better of a partner than LPC with the T&C's they afforded us. Subsequently, AMBS can not afford to subject this relationship to questionable timely or accurate SEC filings.

While this make have been an unfortunate mis-step in our accounting procedures and regulatory filing controls, lets also see this as an end to poor and untimely SEC reporting. Lets get this filing behind us quickly - even if it means having to amend former 10-Q's to set the record straight. That said, I have every confidence in Marcum LLP and Robert Farrell, JD going forward. I hope to and expect to have an update later on today.